Reston, Va.—In a study to determine the diagnostic value of molecular imaging in nodal staging of patients with thyroid cancer, researchers were able for the first time to accurately distinguish between cancerous cells in regional lymph nodes and normal residual thyroid tissue directly after surgery.
Researchers from the University of Erlangen-Nürnberg, Germany, reported in an article in the January issue of The Journal of Nuclear Medicine on the results of a study using a hybrid single photon emission computed tomography-computed tomography (SPECT-CT) camera to determine and locate the spread of cancer cells to nearby lymph nodes.
According to the researchers, the demonstration or exclusion of cancer spread (metastasis) in regional lymph nodes plays a major role in treating the disease since all patients with lymph node metastases are considered to be at high risk for recurrence.
source: SNM
Monday, March 30, 2009
Friday, March 27, 2009
Frost & Sullivan Awards Toshiba America Medical Systems for Innovation in Cardiovascular Imaging Products and Services
NewswireToday - /newswire/ - Mountain View, CA, United States, 01/05/2009 - Based on its recent analysis of the cardiovascular imaging market, Frost & Sullivan recognizes Toshiba America Medical Systems with the 2008 North American Frost & Sullivan Award for Healthcare Innovation.
The company has launched a variety of cardiovascular imaging devices, including Aplio™ Artida, most recently released in the cardiac ultrasound line. This product has taken echocardiography a step ahead of plain 4D imaging by automating complex measurements (wall motion tracking) made possible by 4D imaging. Equally innovative is the company's five-axis cardiovascular X-Ray system, which has proven to be highly popular despite the maturity of the market. Meanwhile, Toshiba's newest Vantage™ magnetic resonance (MR) system has set new standards in contrast-free MR angiography (MRA).
Toshiba also introduced Aquilion® ONE, a groundbreaking computed tomography (CT) system based on a 320-detector architecture, providing high temporal resolution and offering the industry's widest anatomic area coverage per gantry rotation. It enables robust, dynamic imaging of the entire heart in a single heartbeat and at a much lower radiation dose. This capability enhances image quality by eliminating the need to reconstruct images from several cardiac cycles, and enables advanced perfusion studies.
source: Newswire Today
The company has launched a variety of cardiovascular imaging devices, including Aplio™ Artida, most recently released in the cardiac ultrasound line. This product has taken echocardiography a step ahead of plain 4D imaging by automating complex measurements (wall motion tracking) made possible by 4D imaging. Equally innovative is the company's five-axis cardiovascular X-Ray system, which has proven to be highly popular despite the maturity of the market. Meanwhile, Toshiba's newest Vantage™ magnetic resonance (MR) system has set new standards in contrast-free MR angiography (MRA).
Toshiba also introduced Aquilion® ONE, a groundbreaking computed tomography (CT) system based on a 320-detector architecture, providing high temporal resolution and offering the industry's widest anatomic area coverage per gantry rotation. It enables robust, dynamic imaging of the entire heart in a single heartbeat and at a much lower radiation dose. This capability enhances image quality by eliminating the need to reconstruct images from several cardiac cycles, and enables advanced perfusion studies.
source: Newswire Today
Thursday, March 26, 2009
MR Arthrography is More Accurate than MR in Diagnosing Shoulder Tears
MR arthrography of the shoulder allows physicians to better identify tears and provides patients with an accurate diagnosis to determine whether or not surgery is needed, according to a study performed at Neuroskeletal Imaging in Merritt Island, Florida.
The study included 150 patients who underwent both 3T MRI and MR arthrography examinations of the shoulder. “We did the study to see if MR, which is noninvasive, works as well as MR arthrography, an invasive procedure that some patients are fearful of having since contrast has to be injected into the shoulder,” said Thomas Magee, MD, lead author of the study. The study found that MR arthrography was more accurate for making a diagnosis. Sensitivity on conventional MRI for anterior labral tears was 83%; for posterior labral tears was 84%; for SLAP tears was 83%; for supraspinatus tendon tears was 92%; and for partial-thickness articular surface tears was 68%. Sensitivity on MR arthrography on the other hand was significantly higher. Sensitivity for anterior labral tears was 98%; for posterior labral tears was 95%; for SLAP tears was 98%; for supraspinatus tendon tears was 100%; and for partial-thickness articular surface tears was 97%. “With MR arthrography we were able to see things with a high degree of accuracy in the shoulder,” said Dr. Magee.
source: ARRS
The study included 150 patients who underwent both 3T MRI and MR arthrography examinations of the shoulder. “We did the study to see if MR, which is noninvasive, works as well as MR arthrography, an invasive procedure that some patients are fearful of having since contrast has to be injected into the shoulder,” said Thomas Magee, MD, lead author of the study. The study found that MR arthrography was more accurate for making a diagnosis. Sensitivity on conventional MRI for anterior labral tears was 83%; for posterior labral tears was 84%; for SLAP tears was 83%; for supraspinatus tendon tears was 92%; and for partial-thickness articular surface tears was 68%. Sensitivity on MR arthrography on the other hand was significantly higher. Sensitivity for anterior labral tears was 98%; for posterior labral tears was 95%; for SLAP tears was 98%; for supraspinatus tendon tears was 100%; and for partial-thickness articular surface tears was 97%. “With MR arthrography we were able to see things with a high degree of accuracy in the shoulder,” said Dr. Magee.
source: ARRS
Wednesday, March 25, 2009
3T MRI: Highly Effective at Detecting Wrist Ligament Tears, Possibly Eliminating Need for Invasive Arthroscopy
MRI of the wrist at 3T is an effective way to detect wrist ligament tears and in some cases can avoid unnecessary surgery, according to a study performed at Neuroskeletal Imaging in Merritt Island, Florida.
The study included 49 patients who had both 3T MR and arthroscopy; 51 tears were found on arthroscopy. 41 of the 51 tears were also found using 3T MRI. “The resolution with 3T MRI is good. We are able to see the small ligaments a lot better and determine whether or not they are torn,” said Thomas Magee, MD, lead author of the study.
“3T MRI is beneficial to both the patient and the physician. If there is a problem, it provides a road map for the physician to use during surgery and eliminates any type of surgery for those who have normal findings,” said Dr. Magee. “We are able to see bone bruises, cysts and other things that may be pain generators instead of ligament tears,” he said.
source: ARRS
The study included 49 patients who had both 3T MR and arthroscopy; 51 tears were found on arthroscopy. 41 of the 51 tears were also found using 3T MRI. “The resolution with 3T MRI is good. We are able to see the small ligaments a lot better and determine whether or not they are torn,” said Thomas Magee, MD, lead author of the study.
“3T MRI is beneficial to both the patient and the physician. If there is a problem, it provides a road map for the physician to use during surgery and eliminates any type of surgery for those who have normal findings,” said Dr. Magee. “We are able to see bone bruises, cysts and other things that may be pain generators instead of ligament tears,” he said.
source: ARRS
Monday, March 23, 2009
MEDRAD Sponsors PET Research with University of Zurich
WARRENDALE, Pa., Jan. 6 /PRNewswire/ -- MEDRAD, Inc., has signed a research agreement with the University of Zurich to study dynamic PET imaging with the MEDRAD Intego(TM) PET Infusion System. The researchers will utilize MEDRAD's latest technology to more precisely control the radioactive dose delivered during PET imaging procedures.
Specifically, the study will examine patients with tumors in the chest or abdomen and compare standard quantitative techniques, such as standard uptake value (SUV), with more advanced kinetic and compartmental models. One of the primary goals of the research is to explore how controlled delivery technology can enable dynamic imaging by providing additional clinical utility and making these advanced techniques more practical. By enabling the benefit of repeatable infusion of the prescribed FDG dose to all subjects in the study, the Intego System is a key element in the research.
"The research will explore the clinical viability of dynamic imaging with PET," said Dr. Alfred Buck, University of Zurich (Switzerland). The University of Zurich is a leading institution in dynamic PET research, and has licensed its proprietary FDG delivery technology to MEDRAD for use in the Intego PET Infusion System.
source: PR Newswire
Specifically, the study will examine patients with tumors in the chest or abdomen and compare standard quantitative techniques, such as standard uptake value (SUV), with more advanced kinetic and compartmental models. One of the primary goals of the research is to explore how controlled delivery technology can enable dynamic imaging by providing additional clinical utility and making these advanced techniques more practical. By enabling the benefit of repeatable infusion of the prescribed FDG dose to all subjects in the study, the Intego System is a key element in the research.
"The research will explore the clinical viability of dynamic imaging with PET," said Dr. Alfred Buck, University of Zurich (Switzerland). The University of Zurich is a leading institution in dynamic PET research, and has licensed its proprietary FDG delivery technology to MEDRAD for use in the Intego PET Infusion System.
source: PR Newswire
Sunday, March 22, 2009
Ziosoft Receives FDA Clearance for CT Brain Perfusion Application
Redwood City, Calif. January 6, 2009 -- Ziosoft®, Inc., a leader in advanced visualization and analysis software for medical imaging, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its CT brain perfusion application.
The brain perfusion application is a powerful analysis tool used with the Ziostation thin-client system. The software is unique in its ability to provide brain perfusion functionality to clinicians as a thin-client application using standard commercial hardware. This software option aids radiologists in stroke assessment by providing a color map of cerebral blood flow and other perfusion-related parameters from CT images of the brain. The brain perfusion application includes image manipulation tools as well as measurement tools such as cerebral blood volume, blood flow and mean transit time. Ziosoft's brain perfusion application provides radiologists with decision support tools to accurately assess the type and extent of cerebral perfusion disturbance whether viewed in a hospital or at a remote location offering physicians flexibility and efficiency in viewing solutions.
source: Ziosoft
The brain perfusion application is a powerful analysis tool used with the Ziostation thin-client system. The software is unique in its ability to provide brain perfusion functionality to clinicians as a thin-client application using standard commercial hardware. This software option aids radiologists in stroke assessment by providing a color map of cerebral blood flow and other perfusion-related parameters from CT images of the brain. The brain perfusion application includes image manipulation tools as well as measurement tools such as cerebral blood volume, blood flow and mean transit time. Ziosoft's brain perfusion application provides radiologists with decision support tools to accurately assess the type and extent of cerebral perfusion disturbance whether viewed in a hospital or at a remote location offering physicians flexibility and efficiency in viewing solutions.
source: Ziosoft
Friday, March 20, 2009
Largest Radiology Group in New York Purchases Two FONAR UPRIGHT Multi-Position MRIs
MELVILLE, NEW YORK, January 19, 200 - FONAR Corporation (NASDAQ-FONR), The Inventor of MR Scanning™, announced today that it has sold two UPRIGHT® Multi-Position™ MRI scanners to Doshi Diagnostic Imaging Services, P.C., which is among the country’s largest privately held multi-modality imaging companies as well as the largest radiology group in New York. Doshi Diagnostic is headquartered in Bethpage, Long Island, and operates approximately 40 centers in Florida, New Jersey, Long Island, and New York City.Leena Doshi, M.D., President of Doshi Diagnostic said, “We are always looking for the latest and best technology in radiology. The FONAR UPRIGHT® Multi-Position™ MRI is a perfect compliment to existing closed high field and open low field magnets already in our system. Gravity and position can impact a patient’s anatomy, so as the body changes from lying down to being upright, so will the MRI images. Aside from it being a general all-purpose MRI producing high-quality images, the UPRIGHT® MRI will be useful in any condition where the weight-bearing image is relevant, such as spine, ankle, knee and hip.”
source: Fonar
Subscribe to:
Comments (Atom)
Posts
